Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Diversify Advisory Services LLC

Diversify Advisory Services LLC reduced its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 22.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 40,128 shares of the company’s stock after selling 11,700 shares during the period. Diversify Advisory Services LLC’s holdings in Hims & Hers Health were worth $1,020,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Stonekeep Investments LLC boosted its stake in Hims & Hers Health by 5.5% during the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock worth $410,000 after buying an additional 882 shares during the last quarter. Lake Street Private Wealth LLC raised its holdings in shares of Hims & Hers Health by 28.7% during the 4th quarter. Lake Street Private Wealth LLC now owns 133,168 shares of the company’s stock worth $3,220,000 after acquiring an additional 29,721 shares during the period. Carnegie Investment Counsel boosted its position in shares of Hims & Hers Health by 25.5% during the 4th quarter. Carnegie Investment Counsel now owns 376,910 shares of the company’s stock valued at $9,114,000 after acquiring an additional 76,650 shares during the last quarter. CHURCHILL MANAGEMENT Corp purchased a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $445,000. Finally, Cadent Capital Advisors LLC increased its position in Hims & Hers Health by 1.5% during the fourth quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company’s stock worth $1,745,000 after purchasing an additional 1,060 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the completion of the sale, the chief executive officer now owns 67,015 shares in the company, valued at $1,399,273.20. The trade was a 73.81 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $24.44, for a total transaction of $283,039.64. Following the completion of the transaction, the chief financial officer now owns 118,077 shares in the company, valued at $2,885,801.88. This represents a 8.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,072,708 shares of company stock worth $28,940,323 in the last 90 days. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Trading Down 0.5 %

NYSE:HIMS opened at $27.80 on Tuesday. Hims & Hers Health, Inc. has a 12-month low of $8.14 and a 12-month high of $35.02. The firm has a market cap of $6.07 billion, a PE ratio of 63.19 and a beta of 1.31. The stock has a fifty day moving average price of $27.68 and a 200 day moving average price of $21.91.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter last year, the business posted ($0.04) EPS. The business’s quarterly revenue was up 77.1% compared to the same quarter last year. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on HIMS shares. Deutsche Bank Aktiengesellschaft increased their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Morgan Stanley began coverage on Hims & Hers Health in a research note on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price for the company. TD Cowen reaffirmed a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Needham & Company LLC raised their price objective on Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, January 6th. Finally, Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their target price for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $25.13.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.